Literature DB >> 24487565

Development of preclinical models for immunogene therapy of brain cancer: it's not monkey business!

Maciej S Lesniak1.   

Abstract

Entities:  

Year:  2014        PMID： 24487565      PMCID： PMC3916054          DOI： 10.1038/mt.2013.298

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  11 in total

Review 1.  Gene and viral therapy for glioblastoma: a review of clinical trials and future directions.

Authors:  Ahmed Mohyeldin; Ennio Antonio Chiocca
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen.

Authors:  Gwendalyn D King; A K M Ghulam Muhammad; Daniel Larocque; Kyle R Kelson; Weidong Xiong; Chunyan Liu; Nicholas S R Sanderson; Kurt M Kroeger; Maria G Castro; Pedro R Lowenstein
Journal:  Mol Ther       Date:  2011-04-19       Impact factor: 11.454

Review 3.  The art of gene therapy for glioma: a review of the challenging road to the bedside.

Authors:  Alex Tobias; Atique Ahmed; Kyung-Sub Moon; Maciej S Lesniak
Journal:  J Neurol Neurosurg Psychiatry       Date:  2012-09-19       Impact factor: 10.154

4.  A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics.

Authors:  Mariana Puntel; A K M G Muhammad; Marianela Candolfi; Alireza Salem; Kader Yagiz; Catherine Farrokhi; Kurt M Kroeger; Weidong Xiong; James F Curtin; Chunyan Liu; Niyati S Bondale; Jonathan Lerner; Robert N Pechnick; Donna Palmer; Philip Ng; Pedro R Lowenstein; Maria G Castro
Journal:  J Virol       Date:  2010-04-07       Impact factor: 5.103

5.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.

Authors:  Gwendalyn D King; A K M Ghulam Muhammad; James F Curtin; Carlos Barcia; Mariana Puntel; Chunyan Liu; Sarah B Honig; Marianela Candolfi; Sonali Mondkar; Pedro R Lowenstein; Maria G Castro
Journal:  Neuro Oncol       Date:  2007-12-13       Impact factor: 12.300

7.  Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjects.

Authors:  Oliver Klein; Lisa M Ebert; Damien Zanker; Katherine Woods; Bee Shin Tan; Jitka Fucikova; Andreas Behren; Ian D Davis; Eugene Maraskovsky; Weisan Chen; Jonathan Cebon
Journal:  Eur J Immunol       Date:  2012-12-05       Impact factor: 5.532

8.  Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.

Authors:  A K M G Muhammad; M Puntel; M Candolfi; A Salem; K Yagiz; C Farrokhi; K M Kroeger; W Xiong; J F Curtin; C Liu; K Lawrence; N S Bondale; J Lerner; G J Baker; D Foulad; R N Pechnick; D Palmer; P Ng; P R Lowenstein; M G Castro
Journal:  Clin Pharmacol Ther       Date:  2010-02-17       Impact factor: 6.875

9.  Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.

Authors:  Nathan VanderVeen; Christopher Paran; Ashley Appelhans; Johnny Krasinkiewicz; Rosemary Lemons; Henry Appelman; Robert Doherty; Donna Palmer; Philip Ng; Pedro R Lowenstein; Maria G Castro
Journal:  Mol Ther Methods Clin Dev       Date:  2014-02-05       Impact factor: 6.698

10.  Fms-like tyrosine kinase 3 ligand controls formation of regulatory T cells in autoimmune arthritis.

Authors:  Mattias N D Svensson; Sofia E M Andersson; Malin C Erlandsson; Ing-Marie Jonsson; Anna-Karin H Ekwall; Karin M E Andersson; Anders Nilsson; Li Bian; Mikael Brisslert; Maria I Bokarewa
Journal:  PLoS One       Date:  2013-01-21       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.